113 results
8-K
EX-99.1
PLUR
Pluri Inc
29 Sep 22
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
9:57am
Exhibit 99.1
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial … Updates
New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheet
Leading European manufacturer
8-K
EX-99.1
PLUR
Pluri Inc
28 Dec 22
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
4:01pm
Exhibit 99.1
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and
Announcing Food Tech Joint Venture … Proof of Concept
Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat
8-K
EX-99.1
PLUR
Pluri Inc
14 Mar 06
Pluristem Strengthens Business Strategy Company to Focus on Commercializing Cell Therapy Products
12:00am
Exhibit 99.1
Pluristem Strengthens Business Strategy Company to Focus on Commercializing Cell Therapy Products
Haifa, Israel - March 6, 2005 … that the Company is changing its business strategy. Instead of working towards the goal of licensing out the use of its proprietary bioreactor-enabling
8-K
EX-99.1
PLUR
Pluri Inc
25 Jul 22
Pluri CEO Issues Shareholder Update
9:38am
strategy will consist of licensing and joint ventures that we like to call “Pluri focus units”. We expect that these will have separate funding … a brighter tomorrow.
To learn more:
Watch our 90-second explainer video
Dive deeper into Pluri’s strategy
Read today’s press release
Visit Pluri
8-K
EX-99
PLUR
Pluri Inc
28 Feb 05
Pluristem Board Appoints John L. Bakos President
12:00am
on the intersection of technology development, business strategy, finance, procurement of funding, and on the delivery of insightful financial analysis … will allow us to expedite our M&A strategy. With a prestigious Scientific Advisory Board already in place, and with a technology that has delivered
8-K
EX-99.1
0s7y778ysdaykmd3l89b
12 Jan 15
Pluristem Issues Letter to Shareholders
12:00am
8-K
EX-99.1
bm9w q0e0bd77aztawe
9 Jun 14
Regulation FD Disclosure
12:00am
8-K
w7qo2qhcb90
14 Mar 06
Pluristem Strengthens Business Strategy Company to Focus on Commercializing Cell Therapy Products
12:00am
424B5
kzv81mh2l8480 pf
27 Dec 12
Prospectus supplement for primary offering
12:00am
8-K
7o0ylq2egvh9rg
9 Jun 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
x2m2jgdz4 q8b8r0hg3
16 Feb 07
Pluristem Announces Private Equity Investment of $8M
12:00am
8-K
EX-99.1
bcomzqvq1105q7pjve3i
5 Apr 06
Pluristem announces closing of 7% Senior Secured Convertible Debenture Private Placement
12:00am
PRER14A
6w9 vsju2
18 May 20
Preliminary revised proxy
4:06pm